In a report released today, Raju Prasad from William Blair maintained a Buy rating on Global Blood Therapeutics (GBT). The company’s shares closed last Monday at $65.22.

According to, Prasad is a 5-star analyst with an average return of 19.7% and a 56.3% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Global Blood Therapeutics with a $97.58 average price target, which is a 50.2% upside from current levels. In a report issued on February 12, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $105.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $87.54 and a one-year low of $44.17. Currently, Global Blood Therapeutics has an average volume of 1.02M.

Based on the recent corporate insider activity of 59 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GBT in relation to earlier this year. Most recently, in December 2019, Philip Pizzo, a Director at GBT sold 30,000 shares for a total of $2,297,156.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases.

Read More on GBT:

Source link